Spero Total Assets from 2010 to 2024
| SPRO Stock | USD 1.13 0.02 1.74% |
Total Assets | First Reported 2015-12-31 | Previous Quarter 149.9 M | Current Value 135.2 M | Quarterly Volatility 47.3 M |
Check Spero Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spero Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 4.1 M, Depreciation And Amortization of 684.9 K or Interest Expense of 0.0, as well as many indicators such as Price To Sales Ratio of 0.76, Dividend Yield of 0.0 or PTB Ratio of 0.69. Spero financial statements analysis is a perfect complement when working with Spero Therapeutics Valuation or Volatility modules.
Spero | Total Assets |
Latest Spero Therapeutics' Total Assets Growth Pattern
Below is the plot of the Total Assets of Spero Therapeutics over the last few years. Total assets refers to the total amount of Spero Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Spero Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Spero Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Spero Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 182.39 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Spero Total Assets Regression Statistics
| Arithmetic Mean | 75,804,112 | |
| Geometric Mean | 35,408,673 | |
| Coefficient Of Variation | 91.25 | |
| Mean Deviation | 63,173,438 | |
| Median | 93,479,000 | |
| Standard Deviation | 69,169,183 | |
| Sample Variance | 4784.4T | |
| Range | 175.2M | |
| R-Value | 0.89 | |
| Mean Square Error | 1109.4T | |
| R-Squared | 0.78 | |
| Significance | 0.000011 | |
| Slope | 13,700,692 | |
| Total Sum of Squares | 66981.3T |
Spero Total Assets History
Other Fundumenentals of Spero Therapeutics
Spero Therapeutics Total Assets component correlations
Click cells to compare fundamentals
About Spero Therapeutics Financial Statements
Spero Therapeutics investors utilize fundamental indicators, such as Total Assets, to predict how Spero Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 182.4 M | 119.9 M |
Pair Trading with Spero Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Spero Stock
| 0.7 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.66 | ESPR | Esperion Therapeutics | PairCorr |
| 0.54 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.49 | VTRS | Viatris | PairCorr |
| 0.48 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Spero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spero Therapeutics to buy it.
The correlation of Spero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Spero Therapeutics Correlation against competitors. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.753 | Earnings Share 0.08 | Revenue Per Share 2.223 | Quarterly Revenue Growth 2.754 | Return On Assets 0.1048 |
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.